| FIVE-LARGEST-CUSTOMERS |
FIVE-LARGEST-CUSTOMERS |
92%
|
Our five largest customers accounted for approximately 32.4% and 35.0% of our total product revenue in 2024 and 2023, respectively |
| LARGEST-CUSTOMER |
LARGEST-CUSTOMER |
92%
|
As of March 31, 2026, our largest customer accounted for approximately 25% of our total accounts receivable collectively. |
| HALO |
Halozyme Therapeutics, Inc. |
72%
|
Reciprocal relationship from HALO graph: ds. We target large, attractive markets, where ENHANZE-enabled SC delivery has the potential to deliver competitive differentiation and other important benefi… |
| F-11-ZAI-LAB-LIMITED |
F-11-ZAI-LAB-LIMITED |
62%
|
ated statements of operations. F-11 Zai Lab Limited Notes to the Consolidated Financial Statements For the Years Ended December 31, 2024, 2023, and 2022 (e) Cash, Cash Equivalents, and Restricted Cas… |
| F-12-ZAI-LAB-LIMITED |
F-12-ZAI-LAB-LIMITED |
62%
|
from product sales and represent amounts due from its customers. From January 1, 2020, the Company adopted the ASU 2016-13, Credit Losses, Measurement of Credit Losses on Financial Instruments. Accou… |
| F-13-ZAI-LAB-LIMITED |
F-13-ZAI-LAB-LIMITED |
62%
|
from product sales and represent amounts due from its customers. From January 1, 2020, the Company adopted the ASU 2016-13, Credit Losses, Measurement of Credit Losses on Financial Instruments. Accou… |
| F-16-ZAI-LAB-LIMITED |
F-16-ZAI-LAB-LIMITED |
62%
|
the arrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within th… |
| F-18-ZAI-LAB-LIMITED |
F-18-ZAI-LAB-LIMITED |
62%
|
product revenue, respectively for the same periods. Concentration of Credit Risk Financial instruments that are potentially subject to significant concentration of credit risk consist of cash and cas… |
| HUMAN-GENETIC-RESOURCES |
HUMAN-GENETIC-RESOURCES |
62%
|
“plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” or the negative of these terms or similar expressions. Such statements constitute forward-looking s… |
| HUMAN-RESOURCES |
HUMAN-RESOURCES |
62%
|
linical studies, clinical trials, production and distribution, post-market studies, and the monitoring, reporting, and handling of adverse reactions in connection with pharmaceuticals. The marketing … |
| NOVO-HOLDINGS |
NOVO-HOLDINGS |
62%
|
ucture to support the sales of our commercial products. Our sales and marketing teams cover major medical centers across Greater China, and our commercial team has capabilities that cover the product… |
